Trial Profile
A Phase I, First-in-Human Study of PRL3-ZUMAB In Advanced, Solid Tumors and Haematologic Malignancies
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs PRL3 ZUMAB (Primary)
- Indications Acute myeloid leukaemia; Haematological malignancies; Multiple myeloma; Solid tumours
- Focus Adverse reactions; First in man
- 30 Aug 2019 Planned End Date changed from 20 Feb 2019 to 20 Feb 2020.
- 30 Aug 2019 Planned primary completion date changed from 20 Feb 2019 to 20 Feb 2020.
- 23 Jun 2017 New trial record